Major disappointment for Targacept and AstraZeneca in Phase III depression trial
08 November 2011
Sukaina Virji
Please Login to read the full article.
08 November 2011
Sukaina Virji
Please Login to read the full article.
RELATED CONTENT
NEWS
- AstraZeneca to take $381.5 million charge after two major trial failures
- Lundbeck CEO outlines commercial strategy for alcohol-dependency and depression candidates
- Targacept's neuro modulator works in exploratory asthma trial, but not in diabetes
- Forest/Pierre Fabre now aiming for Q4 levomilnacipran MDD filing
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
